# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Samuel Johnson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN008-SYN
- Date: 2026-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Catriona Bell, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week depression check, seen the same day by neurology. **S**

## History of present illness

Mr. Johnson returns two weeks after starting sertraline 50 mg and is seen the same day by Dr. Hassan of neurology. He has taken it every morning. He had mild nausea for the first four days, which has passed, and no agitation or sleep change. His mood is no better yet; he still cannot write and has seen only one friend. The nurse called him after the first week, and he has had two psychotherapy sessions. He told Dr. Hassan about the movements and sounds he has made since boyhood, the urge he feels before each one, his habit of counting his steps at doorways and going back to start again if he gets it wrong, and his fear that all of this, with his low spirits, means he is going mad. **S**

| Element | Detail |
|---|---|
| Sertraline | 50 mg daily for two weeks, every dose taken |
| Side effects | Nausea for four days, resolved |
| Mood | PHQ-9 19 |
| Psychotherapy | Two sessions |
| Tics | Lifelong; urge before each; rituals at doorways |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | Nausea resolved; no diarrhea or bleeding |
| Neurological | Positive | Motor and vocal tics as usual; no weakness, numbness, or headache |
| Psychiatric | Positive | Low mood, guilt, and poor concentration; no agitation; no thoughts of suicide or self-harm |

3 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/80 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 97.6 kg; BMI 29.1 kg/m². All vital signs are synthetic.

PHQ-9: 19. All results are synthetic.

## Change since baseline

- PHQ-9: 21 at baseline, 19 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Large man, untidy; blood pressure 126/80, pulse 80 |
| Neurological | Frequent brief head turns toward the right shoulder with shaking, trunk rocking, rubbing of the left knee, clucking and half-whistling sounds, and forceful exhalations; he can hold them back for a minute when asked, with mounting discomfort; normal tone, strength, reflexes, coordination, and gait; no chorea, dystonia, or tremor |
| Psychiatric | Psychomotor slowing; mood low; logical; no psychosis |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, recurrent, severe** (F33.2). PHQ-9 19, from 21; too early to judge the effect of sertraline. Tolerating it. Safety reviewed: no thoughts of suicide or self-harm; safety plan in place. **S**
   - Continue sertraline 50 mg daily.
   - Weekly psychotherapy.
   - PHQ-9 at four weeks; consider a dose increase then if the response is partial.
2. **Tourette syndrome** (F95.2). The presenting tic disorder now has a diagnosis. Dr. Hassan confirms Tourette syndrome: multiple motor tics and at least one vocal tic since childhood, present for decades, with premonitory urges and brief suppressibility, which distinguish tics from chorea. Yale Global Tic Severity Scale: motor 17, phonic 13, total tic score 30 of 50, impairment 20 of 50. Yale-Brown Obsessive Compulsive Scale 13, mild, with counting and threshold rituals of the tic-related, just-right kind. No ADHD on screening. He was relieved to hear that tics are not madness. **S**
   - Comprehensive Behavioral Intervention for Tics, eight sessions.
   - No tic medication now.
   - Tic severity scale at three and six months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Depression measure (PHQ-9) | At baseline and at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 19, from 21 |
| Medication safety | Sertraline adherence and adverse effects | Every visit in the acute phase; reassess at 2 weeks after starting and after each dose change | Completed today | Two-week check: every dose taken; nausea for four days, resolved; no activation |
| Medication safety | Interaction review (serotonergic drugs; NSAIDs and anticoagulants with an SSRI) | At the start and with any new medicine | Completed today | No other medicines; told to avoid tramadol, triptans without advice, St. John's wort, and regular NSAIDs |
| Survey | Suicide-risk review (PHQ-9 item 9 and structured questions since the last visit), safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; nurse phone check done at one week |
| Referral | Psychotherapy (cognitive behavioral therapy with behavioral activation) | Offer to all with moderate or severe depression | Completed today | Two sessions |
| Survey | Mood Disorder Questionnaire | Once at the start of a depression work-up | Up to date | 3 at intake, negative |
| Survey | Anxiety measure (GAD-7) | At baseline and with PHQ-9 reviews | Up to date | 12 at intake |
| Laboratory | Sodium on an SSRI | Baseline; recheck if symptoms or age 65 or older | Up to date | 140 mmol/L at intake |
| Survey | Tic severity (Yale Global Tic Severity Scale, recorded in the note; no LOINC code is used) | At diagnosis and periodically to judge the need for and response to treatment | Completed today | Total tic score 30 (motor 17, phonic 13); impairment 20 |
| Examination | Assessment for co-occurring conditions (obsessive-compulsive symptoms, ADHD, anxiety, depression) | At diagnosis | Completed today | Obsessive-compulsive symptoms mild (Y-BOCS 13); ADHD screen negative; depression and anxiety under treatment |
| Self-management | Psychoeducation about tics for him and, if he wishes, his household | At diagnosis | Completed today | Natural history of tics explained; tics are not a sign of losing his reason |
| Referral | Comprehensive Behavioral Intervention for Tics | Offer as an initial treatment option | Ordered | Eight sessions with a trained therapist |
| Medication safety | Tic-suppressing medication (alpha-2 agonist, aripiprazole, or other) | When tics cause impairment that behavioral therapy does not relieve | Not indicated | Behavioral therapy first; he prefers to avoid more medicine |
| Referral | Neurology consultation | At the start of evaluation | Completed today | Seen by Dr. Hassan today |

## Goal progress

- PHQ-9 response (at least a 50% fall) by three months and remission (below 5) by six months. In progress; target 2026-09-28. **S**
- Back at daily writing and seeing friends again by three months. In progress; target 2026-06-22. **S**
- Fewer and less disruptive tics, judged by him and by the tic severity scale, by six months. In progress; target 2026-09-28. **S**
- Safety plan in place and reviewed at every visit. In progress; target 2026-09-28. **S**

## Guideline basis

- Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders (Pringsheim T, et al. Neurology 2019;92(19):896-906) (2019), American Academy of Neurology
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Visit in four weeks. Psychotherapy weekly. Behavioral therapy for tics to begin in two weeks. **S**
- Next scheduled visit 2026-05-18: six-week depression review: sertraline dose increase; behavioral therapy for tics under way. **S**
